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ABSTRACT
Introduction: Interleukin (IL)-17 inhibitors are
the most recent class of monoclonal antibodies
approved by the FDA for psoriasis treatment.
Preclinical and phase II studies of brodalumab, a
high-affinity IL-17 receptor monoclonal
antibody, have been encouraging.
Methods: We conducted a literature search
using the PubMed database in order to assess
the efficacy and safety profile of brodalumab.
The search included the following key words:
‘‘psoriasis’’ and ‘‘IL-17’’ or ‘‘brodalumab.’’ We
also reviewed citations within articles to
identify relevant sources.
Results: At week 12, the proportion of patients
attaining a 75% improvement from the baseline
Psoriasis Area and Severity Index (PASI 75) was
similar among the three phase III trials
(AMAGINE-1, 83%; AMAGINE-2, 86%;
AMAGINE-3, 85%). Brodalumab remained
efficacious through 52 weeks of treatment. It
maintained a satisfactory safety profile; the
most frequently reported adverse events
consisted of nasopharyngitis, headache, upper
respiratory tract infection, and arthralgia.
Conclusion: Use of brodalumab revealed prompt
clinical improvement and a favorable short-term
safety profile in phase III trials, although further
extension studies are needed to assess long-term
safety. Based on the results, brodalumab appears
tobeapotent therapeutic option for patientswith
moderate-to-severe plaque-type psoriasis.
Keywords: AMAGINE; Anti-interleukin-17;
Biologics; Brodalumab; Interleukin 17; Phase
III; Psoriasis
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INTRODUCTION
Psoriasis is a common chronic
immune-mediated skin disease that occurs in
3–4% of the adult US population [1]. Symptoms
of psoriasis, which include redness, scaling,
flaking, pruritus, skin tightness, pain, and
bleeding, have a significantly negative impact
on patients’ physical and mental functioning
[2]. Psoriasis also leads to impairment of quality
of life, psychological well-being, and work
productivity [2, 3]. Despite the rapid
development of novel treatment modalities
over the past 2 decades, surveys conducted by
the National Psoriasis Foundation reveal that a
significant portion of patients with psoriasis
remain undertreated relative to the severity of
their disease [3]. These patients will require new
medications with superior long-term efficacy
and safety for the treatment of
moderate-to-severe psoriasis.
Brodalumab is one of three biologic agents,
in addition to secukinumab and ixekizumab,
which targets the interleukin (IL)-17 cytokine
pathway, which has been implicated in the
pathogenesis of psoriasis. IL-17A is one of six
subsets of IL-17 and is regarded as the most
significant subtype in psoriasis development [4,
5]. The cytokine applies its effect by binding the
IL-17 receptor type A (IL-17RA) [6]. TH17 cells
are increased in psoriatic lesions and are
activated by IL-23 to release IL-17 [7–11]. IL-17
plays a part in the stimulation and recruitment
of neutrophils, the defense of neutrophil
apoptosis, and the provocation of psoriasis
angiogenesis [5, 12–14]. Proof of increased
levels of IL-17 mRNA [15] and IL-17 in
psoriatic lesions and in the serum of psoriasis
patients further supports the role of IL-17 in the
pathogenesis of psoriasis [8, 16–19].
Brodalumab is a human immunoglobulin G
(IgG) 2 monoclonal antibody that acts by
specifically inhibiting IL-17RA, thus decreasing
the downstream effect of IL-17 [20]. It binds
with high affinity to IL-17RA and blocks the
biological activity of IL-17A, IL-17F, and IL-25
(IL-17E) [20].
In the following article, we review the results
of the clinical phase III trials establishing the
efficacy and safety of brodalumab in patients
with moderate-to-severe plaque psoriasis. Two
co-primary end points were examined: a 75%
reduction in the Psoriasis Area and Severity
Index (PASI 75) and static physician global
assessment (sPGA) of 0 (clear) or 1
(almost-clear) on a five-point scale by week 12
of treatment. sPGA is a method employed by
investigators to document their assessment of
disease severity, with scores ranging from 0
(clear) to 4 (severe disease). We also report
long-term efficacy results up to 52 weeks in the
clinical trials that have been completed to date.
METHODS
We conducted a systematic English-language
literature search of PubMed, MEDLINE, and
Cochrane databases from January 2003 to May
2016 to identify and evaluate all phase III
randomized clinical trials on efficacy and
safety of brodalumab for plaque psoriasis. Key
search terms included ‘‘brodalumab,’’
‘‘psoriasis,’’ and ‘‘phase III’’ or ‘‘IL-17,’’
‘‘psoriasis,’’ and ‘‘phase III.’’ We also reviewed
citations within articles to identify relevant
resources. Studies that were not in English,
were not phase III, or did not conduct a
randomized controlled trial for plaque
psoriasis on humans were excluded from the
review. This left three phase III clinical trials
that were included in this assessment:
AMAGINE-1, AMAGINE-2, and AMAGINE-3.
Pooled measures of efficacy and incidence of
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adverse events were calculated by tabulating
values from independently conducted studies.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Three major phase III clinical trials,
AMAGINE-1, AMAGINE-2, and AMAGINE-3
(ClinicalTrials.gov identifiers: NCT01708590,
NCT01708603, and NCT01708629,
respectively), were conducted to determine the
efficacy and safety of different doses of
brodalumab compared to placebo [20, 21].
AMAGINE-2 and AMAGINE-3 also compared
brodalumab to ustekinumab. The comparisons
in baseline demographics are shown in Table 1,
while the results from each of these trials are
displayed in Table 2. All three trials were
eventually terminated prematurely by the




This was a randomized, double-blind,
placebo-controlled multicenter trial that
consisted of 661 patients randomly distributed
in a 1:1:1 ratio to receive 210 mg brodalumab,
140 mg brodalumab, or placebo (all given as a
subcutaneous injection on day 1 and weeks 1, 2,
4, 6, 8, and 10) [20]. The study incorporated the
co-primary end points of PASI 75 and sPGA 0 or
1 at week 12. PASI 90, PASI 100, and Psoriasis
Symptom Inventory (PSI) response were
included as secondary end points in the study.
The PSI is a patient-performed symptom
self-assessment that measures psoriasis signs
and symptoms. At 12 weeks, patients receiving
brodalumab were re-randomized to receive
placebo, brodalumab 210 mg, or brodalumab
140 mg every 2 weeks (Q2W) through week 52.
Efficacy
By week 12, the trial demonstrated statistically
significant superiority of brodalumab 210 mg
and brodalumab 140 mg over placebo. The
proportions of patients achieving PASI 75 were
83.3% and 60.3% for brodalumab 210 mg and
140 mg, respectively, compared to 2.7% in
those who took placebo (P\0.001 compared
to placebo). The percentage achieving sPGA 0 or
1 were 75.7% and 53.9% for brodalumab
210 mg and 140 mg, respectively, compared to
1.4% in those who took placebo (P\0.001
compared to placebo). Both dosages of
brodalumab were statistically superior to
placebo in terms of PASI 90, PASI 100, and PSI
(P\0.001 compared to placebo) (Table 2). Data
beyond week 12 revealed that this trend was
sustained through 52 weeks with 83.1% and
70.2% of treatment responders maintaining
sPGA 0 or 1 at week 52 while taking
brodalumab 210 mg Q2W or brodalumab
140 mg Q2W, respectively. This is in contrast
to 0% and 5.1% of patients maintaining sPGA
0/1 at week 52 when switching from
brodalumab 210 mg and brodalumab 140 mg,
respectively, to placebo (P\0.001 compared to
placebo).
Adverse Events
At 12 weeks, a greater proportion of patients
receiving brodalumab 210 mg and brodalumab
140 mg experienced any treatment-related
adverse events (59% and 57.5%, respectively)
or serious adverse events (1.8% and 2.7%,
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Table 2 Primary and secondary end points at week 12 for brodalumab compared to placebo and ustekinumab Disclaimer:
these data were tabulated from independent studies that were not conducted in a head-to-head manner





45 mg or 90 mg



















































































































































sPGA static Physician Global Assessment, PASI Psoriasis Area and Severity Index, PSI Psoriasis Symptom Inventory, CI
conﬁdence interval
* P\0.01 for the comparison with ustekinumab
 P\0.001 for the comparison with placebo
} P[0.05 for the comparison with ustekinumab
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respectively) compared to placebo (any adverse
events, 50.9%; serious adverse events, 1.4%).
The most common adverse events (occurring in
C5% in any treatment group) were
nasopharyngitis, upper respiratory tract
infection, and headache. Most adverse events
brought on by treatment were mild or moderate
in severity with most patients continuing
treatment with brodalumab. Depression was
observed in 0.5% of individuals in each group
taking brodalumab 210 mg, brodalumab
140 mg, and placebo at 12 weeks. There was
one case each of neutropenia and oral
candidiasis by 12 weeks, both cases in the
brodalumab 140 mg group. Through 52 weeks
on brodalumab, no evidence of a dose effect on
adverse event rates was observed. Readers
should interpret the data from this study
cautiously, as results were obtained from the
American Academy of Dermatology meeting
poster session and have not yet been peer
reviewed. Additionally, comparisons in adverse
events are not statistically significant, as the
studies are powered to detect differences in
efficacy rather than rates of adverse events.
AMAGINE-2
Study Design
This was a randomized, double-blind,
placebo-controlled, parallel group multicenter
trial that consisted of 1831 patients randomly
distributed in a 2:2:1:1 ratio to receive either
brodalumab 210 mg or brodalumab 140 mg
(both given as a subcutaneous injection on
day 1 and weeks 1, 2, 4, 6, 8, and 10),
ustekinumab [given as subcutaneous injection
of 45 mg for patients with body weight B100 kg
and 90 mg for patients with body weight
[100 kg, on day 1 and week 4 and every
12 weeks (Q12W) thereafter], or placebo given
as a subcutaneous dummy injection on day 1
and weeks 1, 2, 4, 6, 8, and 10), respectively
[21]. At 12 weeks, patients in the brodalumab
treatment arms were re-randomized in a 2:2:2:1
ratio to receive brodalumab at 210 mg Q2W,
140 mg Q2W, 140 mg every 4 weeks (Q4W), or
140 mg every 8 weeks (Q8W), respectively,
through week 52. Patients originally taking
placebo were switched to brodalumab 210 mg
Q2W at 12 weeks through 52 weeks. Those
taking ustekinumab continued to receive
ustekinumab at the same dose Q12W. The trial
incorporated the 12-week co-primary end
points of PASI 75 and sPGA 0 or 1 in patients
taking brodalumab versus placebo, and PASI
100 in patients taking brodalumab versus
ustekinumab. PASI 90, PASI 100, and PSI
response at week 12 and sPGA 0 or 1 at week
52 were included as secondary end points in the
study.
Efficacy
At 12 weeks, the study demonstrated
statistically significant superiority of
brodalumab 210 mg and brodalumab 140 mg
over placebo. The proportion of patients
achieving PASI 75 were 86.3% and 66.6% for
brodalumab 210 mg and brodalumab 140 mg,
respectively, compared to 8.1% in those who
took placebo (P\0.001 compared to placebo).
The percentages achieving sPGA 0 or 1 were
78.6% and 58.0% for brodalumab 210 mg and
brodalumab 140 mg, respectively, compared to
4.0% in those who took placebo (P\0.001
compared to placebo). In comparison to
ustekinumab 45 mg or 90 mg, brodalumab
210 mg was shown to be statistically superior
in terms of the proportion of patients achieving
sPGA 0 or 1, PASI 90, and PASI 100 (P\0.01
compared to ustekinumab). Both dosages of
brodalumab were also statistically superior to
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placebo in terms of PASI 90, PASI 100, and PSI
response (P\0.001 compared to placebo)
(Table 2). Data beyond 12 weeks revealed that
65% of patients in the brodalumab 210 mg
Q2W group and 43% in the brodalumab 140 mg
Q2W group achieved sPGA 0 or 1 at 52 weeks.
Adverse Events
At 12 weeks, a greater proportion of patients
receiving brodalumab 210 mg and brodalumab
140 mgexperiencedany treatment-relatedadverse
events (57.8% and 60.1%, respectively) compared
to placebo (53.4%). The rates of or serious adverse
events at 12 weeks were 1.0%, 2.1%, and 2.6% for
patients taking brodalumab 210 mg, brodalumab
140 mg, or placebo, respectively. The most
common adverse events were nasopharyngitis,
upper respiratory tract infection, headache, and
arthralgia. Most adverse events brought on by
treatment were mild or moderate in severity with
most patients continuing treatment with
brodalumab. Depression was observed in 0.3% of
individuals on brodalumab 210 mg, 0.7% in those
on brodalumab 140 mg, and 0.3% in those on
placebo at 12 weeks, while there was one suicide
attempt in the brodalumab 210 mg group. By
12 weeks, candida infections were more frequent
in the brodalumab 210 mg groups (1.6%) and
brodalumab 140 mg group (1.3%) compared to
placebo (0.6%). Both the brodalumab 210 mg and
brodalumab 140 mg groups had one case each of
neutropenia by 12 weeks, while placebo had 0
cases. Through 52 weeks, there was one reported
case of completed suicide in a patient who had
started on placebo and switched to brodalumab
210 mgat12 weeks,occurring27 daysafter the last
dose. There was an additional completed suicide
beyond 52 weeks in a patient who had received
brodalumab 210 mg every 2 weeks, occurring
19 days after the last dose. The patient on
brodalumab 210 mg Q2W who had a suicide
attempt prior to 12 weeks also had two further
suicide attempts while on brodalumab 210 mg
Q2Wthroughweek 52. It is important to note that
comparisons in adverse events are not statistically
significant, as the studies are powered to detect




This study employed the same design method
as AMAGINE-2, with a randomized,
double-blind, placebo-controlled, multicenter
trial that consisted of 1881 patients randomly
distributed in a 2:2:1:1 ratio to receive either
brodalumab 210 mg or brodalumab 140 mg
(both given as a subcutaneous injection on
day 1 and weeks 1, 2, 4, 6, 8, and 10),
ustekinumab [given as subcutaneous injection
of 45 mg for patients with body weight B100 kg
and 90 mg for patients with body
weight [100 kg, on day 1 and week 4 and
every 12 weeks (Q12W) thereafter), or placebo
given as a subcutaneous dummy injection on
day 1 and weeks 1, 2, 4, 6, 8, and 10],
respectively [21]. As in AMAGINE-2, at
12 weeks, patients in the brodalumab
treatment arms were re-randomized in a
2:2:2:1 ratio to receive brodalumab at 210 mg
every 2 weeks (Q2W), 140 mg Q2W, 140 mg
every 4 weeks (Q4W), or 140 mg every 8 weeks
(Q8W), respectively, through week 52. Patients
originally taking placebo were switched to
brodalumab 210 mg Q2W at 12 weeks through
52 weeks. Those taking ustekinumab continued
to receive ustekinumab at the same dose Q12W.
The study incorporated the same co-primary
and secondary end points as AMAGINE-2.
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Efficacy
At 12 weeks, the study demonstrated
statistically significant superiority of
brodalumab 210 mg and brodalumab 140 mg
over placebo. The proportion of patients
achieving PASI 75 were 85.1% and 69.2% for
brodalumab 210 mg and brodalumab 140 mg,
respectively, compared to 6.0% in those who
took placebo (P\0.001 compared to placebo).
The percentage achieving sPGA 0 or 1 were
79.6% and 59.9% for brodalumab 210 mg and
brodalumab 140 mg, respectively, compared to
4.1% in those who took placebo (P\0.001
compared to placebo). In comparison to
ustekinumab 45 mg or 90 mg, brodalumab
210 mg was shown to be statistically superior
in terms of the proportion of patients achieving
sPGA 0 or 1, PASI 75, PASI 90, and PASI 100
(P\0.01 compared to ustekinumab). Both
dosages of brodalumab were also statistically
superior to placebo in terms of PASI 90, PASI
100, and PSI response (P\0.001 compared to
placebo) (Table 2). Data beyond 12 weeks
revealed that 61% of patients in the
brodalumab 210 mg Q2W group and 45% in
the brodalumab 140 mg Q2W group achieved
sPGA 0 or 1 at 52 weeks.
Adverse Events
At 12 weeks, a greater proportion of patients
receiving brodalumab 210 mg and brodalumab
140 mg experienced any treatment-related
adverse events (56.8% and 52.6%, respectively)
or serious adverse events (1.4% and 1.6%,
respectively) compared to placebo (adverse
events: 48.6%, serious adverse events: 1.0%).
The most common adverse events were
nasopharyngitis, upper respiratory tract
infection, headache, and arthralgia. Most
adverse events brought on by treatment were
mild or moderate in severity with most patients
continuing treatment with brodalumab.
Depression was observed in 0.3% of
individuals on brodalumab 210 mg, 0.6% in
those on brodalumab 140 mg, and 0.6% in
those on placebo at 12 weeks, with no
reported suicide attempts by this 12-week
point. In this same time interval, candida
infections were more frequent in the
brodalumab 210 mg groups (1.3%) and
brodalumab 140 mg group (0.5%) compared to
placebo (0.3%). There were 12 reported cases of
neutropenia in the brodalumab groups by
12 weeks (7 in the brodalumab 210 mg group
and 5 in the brodalumab 140 mg group), while
placebo had 0 cases. Through 52 weeks and
beyond, there were no reported completed
suicides or attempts of suicide. Important to
note, comparisons in adverse events are not
statistically significant, as the studies are
powered to detect differences in efficacy rather
than rates of adverse events.
POOLED RESULTS
Efficacy
At 12 weeks, each of the studies demonstrated
statistically significant superiority of
brodalumab 210 mg Q2W and brodalumab
140 mg Q2W over placebo (P\0.001 for all
groups compared to placebo). Within these
studies, the pooled proportion of patients
reaching PASI 75 were 85.3% and 64.1% for
brodalumab 210 mg and 140 mg, respectively,
compared to 5.9% in those who took placebo.
The pooled percentage of patients achieving
sPGA 0 or 1 were 78.6% and 58.2% for
brodalumab 210 mg and 140 mg, respectively,
compared to 3.3% among those who took
placebo. Brodalumab was similarly superior to
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placebo in terms of PASI 90 and PASI 100
(Table 2). The pooled data beyond 12 weeks for
all three trials revealed a positive trend in
results, with 64% of the overall patients in the
brodalumab 210 mg Q2W pooled group and
45.9% in the brodalumab 140 mg Q2W pooled
group achieving sPGA 0 or 1 at 52 weeks.
Adverse Events
The pooled proportion of patients who
experienced adverse events at 12 weeks in all
three studies was 57.6% among patients taking
brodalumab 210 mg Q2W, 55.6% among
patients taking brodalumab 140 mg Q2W, and
51.0% among patients on placebo. The most
common adverse events among the studies were
nasopharyngitis, headache, upper respiratory
tract infection, and arthralgia. Throughout all
three studies, 15 out of 2916 patients
experienced neutropenia in the combined
brodalumab dose groups at 12 weeks, while
placebo groups experienced 0 cases of
neutropenia. All cases were mild and transient,
without associated infections. Through
52 weeks and beyond, two completed suicides
were reported in the AMAGINE-2 study among
patients taking brodalumab.
DISCUSSION
Results from the examined phase III clinical
trials demonstrated that brodalumab is a very
potent agent in the treatment of plaque-type
psoriasis. At week 12, the proportions of
patients achieving PASI 75 or sPGA scores of 0
or 1 were higher in the brodalumab 210 mg arm
compared to the brodalumab 140 mg arm, and
both were far superior to the portion of patients
that received placebo (Table 2; Fig. 1).
Brodalumab 210 mg was also found to be
statistically superior to ustekinumab at
12 weeks with respect to PASI 90, PASI 100,












PASI 75 PASI 90 PASI 100 sPGA 0/1
Brodalumab 210 mg Q2W
Brodalumab 140 mg Q2W
Placebo
Ustekinumab 45 mg/90 mg
Fig. 1 Percentage of patients achieving PASI 75, PASI 90,
PASI 100, and sPGA 0 or 1 at the most efﬁcacious phase
III dosage for each drug, at week 12, among the three
AMAGINE trials. Disclaimer: Data were tabulated
from independent studies that were not conducted in a
head-to-head manner. PASI Psoriasis Area and Severity
Index, Q2W Every 2 weeks, sPGA Static Physician Global
Assessment
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results seem encouraging, further long-term
trials are needed. The advantage in
brodalumab is most distinct in regards to the
percentage of patients who attain PASI 90 and
PASI 100 (Table 2). Based on evidence that
patients who reach PASI 90 or PASI 100
experience greater improvement in quality of
life than PASI 75 responders [22], we can
estimate that these efficacy achievements are
more significant than PASI 75 from a patient
perspective. In comparison to secukinumab and
ixekizumab, brodalumab achieves similar
treatment results at 12 weeks. However,
brodalumab appears to deliver greater PASI
100 rates at 12 weeks and better overall
maintenance at 52 weeks, although no
head-to-head studies have been conducted and
research is still in its early states [23]. In any
case, the development of this unique, highly
effective class of biologic therapy provides
optimism for patients whose psoriasis remains
refractory to older biologic agents.
Among the phase III trials of brodalumab,
the most common adverse events included
nasopharyngitis, headache, upper respiratory
tract infection, and arthralgia. The majority of
adverse events were mild or moderate in
severity. Less than 2% of patients experienced
either neutropenia or candida infection while
on brodalumab 210 mg or brodalumab 140 mg
through the first 12 weeks. Neutropenia was
transient and without associated infections, and
candida infections were mild to moderate in
intensity and resolved without discontinuation
of treatment. Anti-IL-17 therapeutics, including
brodalumab, have the theoretical risk of
increasing the incidence of mucocutaneous
candidiasis infection, based on genetic studies
of patients lacking IL-17 immunity [24, 25].
Candida infections were more common among
patients taking brodalumab than in those
taking placebo among the studies we
examined. In comparison to secukinumab and
ixekizumab, no substantial differences were
noted in the safety profile, with
nasopharyngitis, upper respiratory infection,
and headache comprising the most common
adverse events [23]. Both neutropenia and
candida infections generally occurred more
frequently, although not significantly, in
patients on the three therapeutics. Of utmost
significance, the AMAGINE-2 trial included two
patients who completed suicide (one within
52 weeks and another one beyond 52 weeks)
while on brodalumab. Although concerning,
these events do not necessarily constitute a
causative relationship between brodalumab and
suicidal ideation, especially given that patients
with psoriasis are already at higher risk for
depression, suicidal ideation, suicide attempt,
and completed suicide [26, 27]. Regardless,
Amgen, the company involved in the
devlopment of brodalumab, has decided to
withdraw from co-development of the drug
because of worries of a potential black box
warning about suicide, citing ‘‘events of suicidal
ideation and behavior in the brodalumab
program’’ [19]. Valeant Pharmaceuticals has
since assumed a lead role in the further
development of brodalumab [28].
Brodalumab is a human IgG2 monoclonal
antibody that may better achieve full clearance
(PASI 100) relative to the other IL-17A cytokine
specific agents, secukinumab and ixekizumab,
because it is the only treatment in development
that inhibits the IL-17 receptor (IL-17RA).
Although IL-17A is recognized as the most
significant IL-17 isotype in the pathogenesis of
psoriasis [5], IL-17F and IL-25 also interact with
the IL-17 receptor to provoke inflammatory
signaling [4, 20]. The ability of brodalumab to
block the effects of all cytokines that interact
with IL-17RA is likely to contribute to the
higher efficacy observed with brodalumab
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compared to ixekizumab and secukinumab,
whose antagonistic effects are limited to
IL-17A [29]. Both secukinumab and
ixekizumab have passed phase III trials and are
FDA approved, with ixekizumab obtaining
approval most recently on 22 March 2016,
while brodalumab remains in development.
Both brodalumab and secukinumab are fully
human monoclonal antibodies, whereas
ixekizumab is a humanized antibody. A
humanized antibody contains nonhuman
regions, but still behaves very similarly to a
fully human antibodies. In regards to injection
frequency, brodalumab provides a more
advantageous option with only four syringes
injected by the end of the first month for the
210-mg regimen compared to secukinumab,
which necessitates the injection of ten
syringes by the end of the first month for the
300-mg regimen (both dosing regimens are the
highest for the respective drug). Thus far, there
have been no head-to-head comparisons of
brodalumab against secukinumab and
ixekizumab.
In addition to treating psoriasis, brodalumab
has the potential to offer further systemic
benefits. With regards to psoriatic arthritis,
which affects between 5% and 30% of those
with psoriasis, anti-IL-17 agents may have a
critical role, as higher levels of IL-17 and
IL-17RA have been observed within the
synoviocytes and synovial fluid of psoriatic
arthritis patients [30–33]. Consequently, a
phase III clinical trial has shown that
brodalumab was statistically superior to
placebo in the treatment of patients with
active psoriatic arthritis at 12 weeks, as
measured by the proportion of patients
achieving an American College of
Rheumatology 20% improvement response
(ACR20) and 50% improvement response
(ACR50) [34]. Brodalumab is also being tested
as a treatment for asthma and axial
spondyloarthritis [35, 36]. Additionally,
treatment of the inflammatory state
underlying psoriasis has the ability to reduce
the incidence of cardiovascular disease [37].
Increased IL-17 has been detected in
atherosclerotic plaques [38] and is believed to
pair with other inflammatory signals in forming
plaques [39]. These observations together
convey the possibility of using IL-17 pathway
antagonists to treat not only psoriasis, but also
psoriatic arthritis and to reduce the risk of
cardiovascular disease in those with psoriasis
[40].
CONCLUSION
Brodalumab has generated encouraging data for
efficacy and safety in the treatment of chronic
plaque psoriasis. The phase III clinical trials
results suggest that brodalumab 210 mg and
brodalumab 140 mg dosed every 2 weeks are far
superior statistically to placebo in all categories
at 12 weeks and better able to achieve complete
clearance compared to the contemporary
biologic agent ustekinumab. Further results
from open-label extension studies are required
to validate the promising long-term efficacy and
safety profile of this unique therapeutic.
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